In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other susceptible mycobacteria. In addition, results of clinical trials in leprosy have been highly encouraging. Rifampin appears to induce light chain proteinuria in a majority of patients and has been implicated in suppression of both humoral and cell-mediated immune responses. However, these effects appear to have been of little consequence to treated patients. A variety of possibly immunologically mediated reactions to rifampin has been closely associated with irregular administration of the drug. These reactions and hepatic toxcity may be preventable in many patients. Rifampin or one of its congeners, alone or in combination with other antibiotics, may prove useful in treatment of various infectious, and possibly malignant, diseases.
{"title":"Rifampin.","authors":"M. J. Reilly","doi":"10.32388/w4ddgy","DOIUrl":"https://doi.org/10.32388/w4ddgy","url":null,"abstract":"In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other susceptible mycobacteria. In addition, results of clinical trials in leprosy have been highly encouraging. Rifampin appears to induce light chain proteinuria in a majority of patients and has been implicated in suppression of both humoral and cell-mediated immune responses. However, these effects appear to have been of little consequence to treated patients. A variety of possibly immunologically mediated reactions to rifampin has been closely associated with irregular administration of the drug. These reactions and hepatic toxcity may be preventable in many patients. Rifampin or one of its congeners, alone or in combination with other antibiotics, may prove useful in treatment of various infectious, and possibly malignant, diseases.","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"6 1","pages":"176-8"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87430731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A formulary is a continually updated list of medications and related information, representing the clinical judgment of pharmacists, physicians, and other experts in the diagnosis and treatment of disease and promotion of health. A formulary includes, but is not limited to, a list of medications and medication-associated products or devices, medication-use policies, important ancillary drug information, decisionsupport tools, and organizational guidelines. The multiplicity of medications available, the complexities surrounding their safe and effective use, and differences in their relative value make it necessary for health systems to have medication-use policies that promote rational, evidence-based, clinically appropriate, safe, and cost-effective medication therapy. The formulary system is the ongoing process through which a health care organization establishes policies on the use of drugs, therapies, and drug-related products and identifies those that are most medically appropriate and cost-effective to best serve the health interests of a given patient population.
{"title":"ASHP statement on the pharmacy and therapeutics committee.","authors":"","doi":"10.1093/ajhp/43.11.2841","DOIUrl":"https://doi.org/10.1093/ajhp/43.11.2841","url":null,"abstract":"A formulary is a continually updated list of medications and related information, representing the clinical judgment of pharmacists, physicians, and other experts in the diagnosis and treatment of disease and promotion of health. A formulary includes, but is not limited to, a list of medications and medication-associated products or devices, medication-use policies, important ancillary drug information, decisionsupport tools, and organizational guidelines. The multiplicity of medications available, the complexities surrounding their safe and effective use, and differences in their relative value make it necessary for health systems to have medication-use policies that promote rational, evidence-based, clinically appropriate, safe, and cost-effective medication therapy. The formulary system is the ongoing process through which a health care organization establishes policies on the use of drugs, therapies, and drug-related products and identifies those that are most medically appropriate and cost-effective to best serve the health interests of a given patient population.","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"206 1","pages":"2841-2"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88582384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-03DOI: 10.1787/health_glance_ap-2014-33-en
C. Talley
These barriers can negatively impact the ability of some people to access healthcare. For example, refugees may experience systemic-level barriers in the form of lack of access to provincial healthcare coverage. People who use drugs may experience both individualand systemic-level barriers in the form of mental illness, stigma and discrimination, and lack of providers experienced in the care of this population.
{"title":"Access to health care.","authors":"C. Talley","doi":"10.1787/health_glance_ap-2014-33-en","DOIUrl":"https://doi.org/10.1787/health_glance_ap-2014-33-en","url":null,"abstract":"These barriers can negatively impact the ability of some people to access healthcare. For example, refugees may experience systemic-level barriers in the form of lack of access to provincial healthcare coverage. People who use drugs may experience both individualand systemic-level barriers in the form of mental illness, stigma and discrimination, and lack of providers experienced in the care of this population.","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75585658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel T. Abazia, P. Anderson, L. Azzopardi, K. R. Baker, James L. Besier, J. Bootman, D. Bowyer, M. Brady, M. Chrymko, J. Cranston, S. Dzierba, M. Gaunt, P. C. Hagan, R. W. Hammond, E. Hola, P. Kienle, Katharine Kiser, T. L. Kurt, T. R. Lanese, Rosario J. Lazzaro, M. E. Liter, P. Malone, C. Morello, Richard O'Brocta, F. Odedina, J. Ponto, C. W. Quap, M. Rouse, M. Schlaifer, Shelley H. Schliesser, M. Shepherd, Jonalan Smith, A. Vaida, W. Wade, T. Woller, J. Woon
The multiplicity of drugs available and the complexities surrounding their safe and effective use make it necessary for organized health-care settings to have a sound program for maximizing rational drug use. The pharmacy and therapeutics (P&T) committee, or its equivalent, is the organizational keystone to this program. The P&T committee evaluates the clinical use of drugs, develops policies for managing drug use and drug administration, and manages the formulary system. This committee is composed of physicians, pharmacists, and other health professionals selected with the guidance of the medical staff. It is a policy-recommending body to the medical staff and the administration of the organization on matters related to the therapeutic use of drugs.
{"title":"ASHP statement on the pharmacy and therapeutics committee.","authors":"Daniel T. Abazia, P. Anderson, L. Azzopardi, K. R. Baker, James L. Besier, J. Bootman, D. Bowyer, M. Brady, M. Chrymko, J. Cranston, S. Dzierba, M. Gaunt, P. C. Hagan, R. W. Hammond, E. Hola, P. Kienle, Katharine Kiser, T. L. Kurt, T. R. Lanese, Rosario J. Lazzaro, M. E. Liter, P. Malone, C. Morello, Richard O'Brocta, F. Odedina, J. Ponto, C. W. Quap, M. Rouse, M. Schlaifer, Shelley H. Schliesser, M. Shepherd, Jonalan Smith, A. Vaida, W. Wade, T. Woller, J. Woon","doi":"10.2146/AJHP080413","DOIUrl":"https://doi.org/10.2146/AJHP080413","url":null,"abstract":"The multiplicity of drugs available and the complexities surrounding their safe and effective use make it necessary for organized health-care settings to have a sound program for maximizing rational drug use. The pharmacy and therapeutics (P&T) committee, or its equivalent, is the organizational keystone to this program. The P&T committee evaluates the clinical use of drugs, develops policies for managing drug use and drug administration, and manages the formulary system. This committee is composed of physicians, pharmacists, and other health professionals selected with the guidance of the medical staff. It is a policy-recommending body to the medical staff and the administration of the organization on matters related to the therapeutic use of drugs.","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"23 1","pages":"2008-9"},"PeriodicalIF":0.0,"publicationDate":"2008-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87342030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent research on the role of clozapine in the treatment of Parkinson's disease and other movement disorders is discussed. Most clinical trials have shown resolution of or improvement in psychotic symptoms accompanying Parkinson's disease without worsening of parkinsonian symptoms. Adverse effects appear to be mild at dosages of < 100 mg/day; sedation is the most frequent problem. Most of these studies have serious limitations, however; until better studies have been completed, the decision to use clozapine for Parkinson's disease-related psychosis should be made on a case-by-case basis, with thorough evaluation of risks, benefits, and other therapeutic options. Some patients with Parkinson's disease have shown improvement in tremor and other abnormal movements when given clozapine. Clozapine cannot be recommended for treating tardive dyskinesia on the basis of the research done so far; some trials show dramatic resolution of symptoms, others no benefit. Anticholinergics or dopamine-reuptake inhibitors should be considered before clozapine is given to patients with tardive dyskinesia because of clozapine's potential for serious adverse effects. A few patients with Huntington's disease have responded to clozapine, but again no conclusions can be drawn. Clozapine appears to offer no real advantage over haloperidol for treating choreiform movements in Huntington's disease. The frequency of tics in Tourette's syndrome does not seem to be reduced by clozapine. Clozapine has shown some efficacy as a treatment for psychosis and abnormal movements in Parkinson's disease. Results have been less promising for other movement disorders. Further study in larger populations is needed before any definitive conclusions about clozapine's place in movement disorder therapy can be made.
{"title":"Clozapine therapy for Parkinson's disease and other movement disorders.","authors":"C Pfeiffer, M L Wagner","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent research on the role of clozapine in the treatment of Parkinson's disease and other movement disorders is discussed. Most clinical trials have shown resolution of or improvement in psychotic symptoms accompanying Parkinson's disease without worsening of parkinsonian symptoms. Adverse effects appear to be mild at dosages of < 100 mg/day; sedation is the most frequent problem. Most of these studies have serious limitations, however; until better studies have been completed, the decision to use clozapine for Parkinson's disease-related psychosis should be made on a case-by-case basis, with thorough evaluation of risks, benefits, and other therapeutic options. Some patients with Parkinson's disease have shown improvement in tremor and other abnormal movements when given clozapine. Clozapine cannot be recommended for treating tardive dyskinesia on the basis of the research done so far; some trials show dramatic resolution of symptoms, others no benefit. Anticholinergics or dopamine-reuptake inhibitors should be considered before clozapine is given to patients with tardive dyskinesia because of clozapine's potential for serious adverse effects. A few patients with Huntington's disease have responded to clozapine, but again no conclusions can be drawn. Clozapine appears to offer no real advantage over haloperidol for treating choreiform movements in Huntington's disease. The frequency of tics in Tourette's syndrome does not seem to be reduced by clozapine. Clozapine has shown some efficacy as a treatment for psychosis and abnormal movements in Parkinson's disease. Results have been less promising for other movement disorders. Further study in larger populations is needed before any definitive conclusions about clozapine's place in movement disorder therapy can be made.</p>","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 24","pages":"3047-53"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18856118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Improved extemporaneous formulation of cyclosporine ophthalmic drops.","authors":"D W Mueller","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 24","pages":"3080-1"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18856126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Staffing pharmacies to meet the demands of patient-oriented care.","authors":"D. McAllister, D. A. Rittenback","doi":"10.1093/AJHP/51.24.3024","DOIUrl":"https://doi.org/10.1093/AJHP/51.24.3024","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"22 1","pages":"3024-5"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89041300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Opportunities for alliances between industry and pharmacy.","authors":"G B Rosenberg","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 24","pages":"3061-5"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18856122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Subtleties of managing acetaminophen poisoning.","authors":"S R Rose","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 24","pages":"3065-8"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18856123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"National health care reform, Part 2: Response to pharmacists.","authors":"W A Zellmer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 24","pages":"3096"},"PeriodicalIF":0.0,"publicationDate":"1994-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18856129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：